SWOG S0925研究:西妥木单抗联合雄激素剥夺治疗新发转移性激素敏感性前列腺癌的生存结局与风险分组验证
SWOG S0925是一项随机II期试验,纳入210例新发转移性激素敏感性前列腺癌患者,比较雄激素剥夺联合或不联合西妥木单抗的疗效。成熟生存分析显示,两组在总生存、影像学无进展生存和去势抵抗无生存方面均无显著差异。基线风险分组和疾病体积具有预后价值,其中疾病体积提供更多预后信息,PSA治疗反应是生存的强中间终点。
要点
- 西妥木单抗联合雄激素剥夺未改善新发转移性激素敏感性前列腺癌患者生存。
- 基线高风险和高疾病体积均与更差生存相关,疾病体积预后信息更丰富。
- 28周PSA未达不可测水平者生存更差,PSA反应是强中间终点。
核心结论
- 在新发转移性激素敏感性前列腺癌中,雄激素剥夺联合西妥木单抗较单用雄激素剥夺未改善总生存、影像学无进展生存或去势抵抗无生存。
- 基线风险分组和疾病体积具有预后价值,疾病体积对生存数据的拟合优于风险分组。
- 28周PSA治疗反应是生存的强中间终点。
研究设计与样本
- 随机II期试验SWOG S0925,纳入210例新发转移性激素敏感性前列腺癌患者,随机分配至雄激素剥夺联合或不联合西妥木单抗,每组105例。
- 采用Kaplan-Meier曲线分析总生存、影像学无进展生存和去势抵抗无生存,并按治疗组、疾病体积和风险分组比较。
- 通过协变量调整的Cox比例风险模型(调整疾病体积和风险)探索治疗组间生存差异。
主要发现
- 治疗组间总生存无差异(HR 1.01 [0.70-1.45];p = 0.97)。
- 治疗组间影像学无进展生存无差异(HR 1.17 [0.85-1.60];p = 0.35)。
- 治疗组间去势抵抗无生存无差异(HR 1.02 [0.75-1.41];p = 0.88)。
- 基线时105/198(53.0%)患者具有高风险特征,119/210(56.7%)具有高疾病体积;16.7%患者风险与体积分类不一致。
- 高风险(HR 1.89 [1.29-2.80];p = 0.001)和高疾病体积(HR 2.75 [1.84-4.10];p < 0.0001)与更差生存相关。
临床怎么用
- 对于新发转移性激素敏感性前列腺癌,不推荐在雄激素剥夺基础上常规联合西妥木单抗。
- 基线疾病体积可提供比风险分组更强的预后信息,可用于风险分层。
- 28周PSA反应可作为生存的中间终点,PSA未达不可测者需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cixutumumab, a monoclonal antibody targeting insulin-like growth factor I receptor, did not improve undetectable prostate-specific antigen (PSA) rate at 28 weeks when combined with androgen deprivation in the randomized phase II SWOG S0925 trial for patients with new metastatic hormone-sensitive prostate cancer. We now present mature survival analyses, along with pre-specified secondary and exploratory endpoints. METHODS: We randomized 210 patients to androgen deprivation with or without cixutumumab, 105 per treatment arm. We used Kaplan-Meier curves to analyze overall survival, radiographic progression-free survival, and castration resistance-free survival by treatment arm, disease volume, and risk group. We explored differences in survival by treatment arm via covariate-adjusted Cox proportional hazards models adjusted for disease volume and risk. RESULTS: No difference was seen between treatment arms in overall survival (HR 1.01 [0.70-1.45]; p = 0.97), radiographic progression-free survival (HR 1.17 [0.85-1.60]; p = 0.35), or castration resistance-free survival (HR 1.02 [0.75-1.41]; p = 0.88). At baseline, 105/198 (53.0%) patients had high-risk features and 119/210 (56.7%) had high-volume disease; 16.7% of patients had discordant classifications of high or low category for risk and volume. Adjusting for risk or volume yielded no differences in overall survival between arms. Inferior survival was observed in high-risk (HR 1.89 [1.29-2.80]; p = 0.001) and high-volume (HR 2.75 [1.84-4.10]; p < 0.0001) disease. Disease volume was a better fit to survival data than risk group (AIC 878.3 vs. 889.2). Compared to patients achieving undetectable PSA at 28 weeks, inferior survival was observed in patients whose PSA was >0.2 to ≤4.0 ng/mL (HR 3.72 [1.99-6.95]; p < 0.0001) or >4.0 ng/mL (HR 7.13 [4.24-11.9]; p < 0.0001). CONCLUSIONS: In new metastatic hormone-sensitive prostate cancer, addition of cixutumumab to androgen deprivation did not improve survival. Baseline risk and disease volume carried prognostic value for this distinct trial population, although disease volume added more prognostic information. PSA treatment response was a strong intermediate endpoint for survival.
引用
- Wong RL, Duong MT, Tangen CM, et al. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32055002. doi:10.1038/s41391-020-0210-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。